
REtropical SArcoma Registry

RESAR

November 2021 update

Dario Callegaro
Istituto Nazionale Tumori, Milan, Italy





ENROLLED PATIENTS


RESAR

2595 patients
(+527 from Feb 2021)

As of Oct 2021

45 (+6 since Feb 2021)


Centers enrolling





ENROLLED PATIENTS

RESAR





RESAR RECRUITING CENTERS As of October 2021

45 centers
in 5
continents


- 6 more centers already with IRB approval and ready to

Institution	City	State	Institution	City	State
Netherlands Cancer Institute	Amsterdam	The Netherlands	Maisonneuve-Rosemont Hospital	Montreal	Canada
Winship Cancer Institute, Emory University	Atlanta	USA	McGill University	Montreal	Canada
Johns Hopkins University	Baltimore	USA	N.N. Blokhin Research Center of Oncology	Moskow	Russia
Hospital Sant Pau	Barcelona	Spain	Ludwig Maximilian University	Munich	Germany
Mary Bird Perkins Cancer Center	Baton Rouge	USA	HCU "Virgen de la Arrixaca"	Murcia	Spain
Peking University International Hospital	Beijing	China	The Ottawa Hospital	Ottawa	Canada
Queen Elizabeth Hospital Birmingham	Birmingham	UK	Veneto Institute of Oncology	Padova	Italy
Institut Bergonié	Bordeaux	France	Institut Curie	Paris	France
BWH / Dana-Farber Cancer Institute	Boston	USA	IPO Porto	Porto	Portugal
Princess Alexandra Hospital	Brisbane	Australia	Campus Biomedico	Roma	Italy
Roswell Park Comprehensive Cancer Center	Buffalo	USA	Humanitas Cancer Center	Rozzano	Italy
Candiolo Cancer Institute	Candiolo	Italy	UC San Diego	San Diego	USA
The Ohio State University	Columbus	USA	A.C. Camargo Cancer Center	Sao Paulo	Brazil
Mayo Clinic	Jacksonville	USA	University of Washington	Seattle	USA
Leiden University Medical Center	Leiden	The Netherlands	Samsung Medical Center	Seoul	South Korea
Liverpool University Hospitals	Liverpool	UK	Royal Prince Alfred Hospital	Sydney	Australia
Institute of Oncology Ljubljana	Ljubljana	Slovenia	Moffitt Cancer Center	Tampa	USA
Royal Marsden Hospital	London	UK	Tel-Aviv Sourasky Medical Center	Tel-Aviv	Israel
University of Southern California	Los Angeles	USA	National Cancer Center Hospital	Tokyo	Japan
Mannheim University Medical Center	Mannheim	Germany	Mount Sinai / Princess Margaret	Toronto	Canada
Peter MacCallum Cancer Center	Melbourne	Australia	Ospedale Borgo Roma	Verona	Italy
Fondazione IRCCS Istituto Nazionale dei Tumori	Milano	Italy	Maria Sklodowska-Curie Cancer Center	Warsaw	Poland
European Institute of Oncology	Milano	Italy			



ENROLLED PATIENTS


RESAR





ENROLLED PATIENTS

RESAR



ENROLLED PATIENTS – WHO ARE THEY?



Sex	
Male	53%
Female	47%
Histology	
WDLPS	23%
DDLPS	42%
LMS	18%
SFT	5%
MPNST	1%
Multifocality	7%
Site	
Retroperitoneal	88%
Other (mesent./peritoneum/pelvis)	12%
Preop RTx	19%
Preop CTx	15%
R2	5%
Tumor rupture	5%
Clavien-Dindo complic >2	25%
Reoperation due to complications	11%

Complexity Score Project
(Dr. M. Fairweather)
Timeframe: 2017-2020
N=1092

RESAR

- November 2021 update -



Thanks!